UCB (ENXTBR:UCB) just dedicated the future site of a major U.S. biologics manufacturing campus in Gwinnett County, Georgia, a multibillion euro project that could reshape its American footprint.
Set against this expansion news, UCB’s share price at €202.0 has had a weaker patch recently, with a 30 day share price return down 4.04% and a 90 day move down 15.02%, while the 3 year total shareholder return of 162.98% still points to strong longer term gains.
Scan for other biopharma players making big capacity bets like UCB by reviewing the hand picked list of solid balance sheet and fundamentals (203 results) alongside this Georgia expansion story.
UCB is pouring billions into capacity just as the share price has pulled back hard. Is most of the rerating already in the rear view, or is the valuation still leaving real upside on the table?
Most Popular Narrative: 11% Undervalued
On one side, UCB last closed at €202.0. On the other, the most followed narrative on Simply Wall St pegs fair value at about €227. That gap is what frames the entire debate around whether this Georgia build out is being fully recognised in the current price.
The fair value shown on this page is a discounted cash flow, because that is what this platform's format is built on. My full method at StoxEurope ran five models on UCB. Two independent ones, the DCF and a free cash flow to equity model, corroborated within a 6.8 % band, and the platform published a consolidated estimate of 227.49 euro, band 227.49 to 243.49. The 243.49 in the field above is the top of that band, not the conclusion. The published estimate is the panel's median, which is the FCFE figure.
See why 4 investors see UCB as 11% undervalued.
According to StoxEurope, that consolidated fair value range of €227.49 to €243.49 rests on cash flow driven work rather than a single headline metric. UCB screens as about 11% below that €227.49 median, which is where the undervaluation label comes from in the Simply Wall St narrative.
Result: Fair Value of €227.49 (UNDERVALUED)
Still, UCB’s story could change quickly if key pipeline assets underperform or if the heavy U.S. manufacturing build strains returns more than expected.
Find out about the key risks to this UCB narrative.
Next Steps
If this analysis leaves you torn between caution and optimism, move quickly to test the numbers for yourself so you can take a clear stance. Then pressure test that view against the 5 key rewards.
Looking for more UCB investment ideas?
UCB is only one piece of your portfolio puzzle. Broaden your opportunity set by lining it up against other ideas that match your risk and return preferences.
- Target resilience by comparing UCB against a 224 resilient stocks with low risk scores that may offer steadier profiles when markets swing.
- Hunt for mispriced quality by weighing this stock beside a 188 high quality undervalued stocks that might trade below what underlying fundamentals suggest.
- Spot fresh potential by scanning a 616 high quality undiscovered gems before attention and liquidity crowd in.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com